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A selective urea transporter UT-A1 inhibitor would be a novel type of diuretic, likely with less undesirable side
effects than conventional diuretics, because it acts on the last portion of the nephron. In this issue of
Chemistry & Biology, Esteva-Font and colleagues develop such an inhibitor by using a clever high-
throughput screening assay and document its selectivity.Diuretics are commonly used to treat
conditions associated with volume over-
load, such as congestive heart failure,
cirrhosis, and nephrotic syndrome.
Diuretics are also a mainstay for the treat-
ment of hypertension. Currently used
diuretics act by inhibiting sodium trans-
port in different segments of the kidney
tubule (Figure 1). The loop diuretics,
such as furosemide and others in this
class, act by inhibiting the Na-K-2Cl
co-transporter, NKCC2, in the thick
ascending limb of the loop of Henle. This
segment is responsible for 25%of sodium
reabsorption, making them powerful di-
uretics. The thiazide diuretics act by inhib-Figure 1. Diagram Showing a Nephron and a Collecting Duct
Diagram of the loop of Henle, distal convoluted tubule, and collecting duct
showing the names and location of themajor sodium (Na-K-2Cl co-transporter
NKCC2 and Na-Cl co-transporter NCC), water (aquaporins AQP2–AQP4), and
urea transport (urea transporter UT-A1, UT-A2, and UT-A3) proteins. Loop
diuretics act by inhibiting sodium transport by NKCC2. Thiazide diuretics act
by inhibiting sodium transport by NCC. The newly identified urea transporter
inhibitor may act as a diuretic by inhibiting UT-A1.iting the Na-Cl co-transporter
in the distal convoluted tu-
bule, which is responsible for
5% of sodium reabsorption.
Diuretics such as amiloride,
triamterene, or spironolac-
tone act by inhibiting sodium
reabsorption in the collecting
duct by inhibiting either the
epithelial sodium channel or
the mineralocorticoid recep-
tor. These diuretics are less
potent in terms of inducing
a natriuresis but have the
benefit of causing less kaliu-
resis. In patients with hard
to treat volume overload, di-
uretics with different mecha-
nisms of action, and which
act on different nephron seg-
ments, are often combined.
These various medications
lead to an effective natriuresis
and diuresis, but they can
cause undesired electrolyte
abnormalities.In this issue of Chemistry & Biology,
Esteva-Font et al. (2013) report on the
development of a very clever high-
throughput screening assay to identify
small molecule inhibitors of the urea
transporter UT-A1. They transfected UT-
A1-MDCK cells (Fro¨hlich, et al., 2004)
with the aquaporin-1 (AQP1) water chan-
nel to ensure that these cells have a
much higher water permeability than
urea permeability, thereby permitting
them to develop a screen based upon
changes in cell volume in response to an
imposed urea gradient. Transfecting
AQP1 into the UT-A1-MDCK cells was
key to creating an appropriate cell systemChemistry & Biology 20, October 24, 2013 ªfor high-throughput screening. They then
transfected the cells with a chloride-
sensing, genetically encoded fluorescent
protein so they could use a change in
fluorescence in their screening assay.
The innovative creation of UT-A1-MDCK
cells transfected with AQP1 and the
fluorescent protein resulted in a cell line
that was amenable to high-throughput
screening and was critical to the success-
ful identification of small molecule inhibi-
tors of UT-A1.
The existence of urea transporter
proteins in the inner medullary collecting
duct (IMCD), which is where UT-A1
is expressed, was initially proposed2013 Elseviin 1987 (Sands, et al.,
1987). The SLC14A family of
urea transporters has twoma-
jor subgroups, designated
UT-A (SLC14A2) and UT-B
(SLC14A1) (reviewed in (Klein,
et al., 2011, 2012). The UT-A
urea transporters consist of
six distinct isoforms, three of
which are located primarily
in the kidney medulla (Fig-
ure 1). UT-A1, which is the
focus of the current study,
and UT-A3 are expressed in
the IMCD. The IMCD is the
last nephron segment through
which tubular fluid (urine)
passes before entering the
ureter. UT-A2 is expressed in
the thin descending limb of
the loopofHenle.UT-B1 is ex-
pressed in descending vasa
recta and red blood cells.
Urine concentrating ability,
and hence the ability to
conserve water, is reduced iner Ltd All rights reserved 1201
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A1/UT-A3, UT-A2, UT-B1, or UT-A2 and
UT-B1 (reviewed in Klein, et al., 2011,
2012). Thus, an inhibitor of any of these
urea transporters may result in a diuresis.
Urea plays a critical role in the urinary
concentrating mechanism and in the
maintenance of water balance (reviewed
in Sands and Layton, 2013 and Sands,
et al., 2011). Protein-deprivation or a
low-protein diet reduces maximal urine
concentrating ability, and hence the abil-
ity to conserve water, and is restored by
urea infusion. As mentioned above, mice
with genetic knock-out of both IMCD
urea transporters, UT-A1 and UT-A3,
have a urine concentrating defect. The
polyuria in these mice results from the
absence of urea transport in their IMCD
(Fenton, et al., 2004).
Here, Esteva-Font et al. (2013) report a
selective inhibitor of the UT-A1 urea trans-
porter as well as a UT-A1/UT-B1 nonse-
lective inhibitor. Whereas an inhibitor of
UT-B1 that is metabolically stable and
works at nanomolar potency has been re-
ported previously (Anderson, et al., 2012;
Yao, et al., 2012), this study is, to the
best of my knowledge, the first to report
a UT-A1 selective inhibitor. Further devel-
opment and in vivo testing of this intriguing1202 Chemistry & Biology 20, October 24, 20compound would be quite exciting.
Although future studies in animals will be
needed to assess the ability of UT-A1 in-
hibitors to induce and sustain a diuresis,
it seems likely that UT-A1 inhibitors will
be effective. A UT-A1 inhibitor is particu-
larly attractive as a drug target, because
having a diuretic that works by inhibiting
urea transport in the last nephron segment
offers the exciting possibility that it will
have less undesirable side effects on elec-
trolytes than the conventional diuretics
that inhibit sodium transport in the thick
ascending limb or distal convoluted tu-
bule. In addition, a UT-A1 inhibitor would
have a different mechanism of action
from other diuretics and would be the first
diuretic to act in the IMCD. This opens the
possibility for combination therapy with
other diuretics, in addition tomonotherapy
with a UT-A1 inhibitor.
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In this issue of Chemistry & Biology, Jahnsen and colleagues describe a multimodal mechanism of action of
an unusual peptide-peptoid hybrid with broad-spectrum antibacterial activity. They demonstrate that the
molecule has effects on many aspects of bacterial metabolism and also modulates host immune responses.Pathogenic, multi-drug-resistant bacterial
strains are becoming increasingly com-
mon. Thus, development of new antibac-
terial compounds is of great interest. One
line of research that has achieved much
attention is host defense peptides. Thesepeptides function, at least in part, by in-
serting into the membranes of bacteria
and depolarizing them. Treatment of bac-
teria with helical defense peptides such
as mellittin results in bacterial cell lysis.
Unfortunately, there has been limited suc-cess in bringing these peptides into the
clinic. Toxicity is an issue, because a
huge selectivity for insertion into bacterial
membranes rather than the membranes
of eukaryotic cells is required, as is the sta-
bility of peptides in serum.
